Initial Treatment for Generalized Hives

Distinguishing Hives from Anaphylaxis

The American Academy of Allergy, Asthma, and Immunology recommends anaphylaxis requires immediate intramuscular epinephrine (0.3-0.5 mg of 1:1000 solution) if the patient has generalized hives PLUS respiratory symptoms, cardiovascular symptoms, or gastrointestinal symptoms occurring suddenly after allergen exposure 4, 5
Isolated generalized urticaria without systemic symptoms should be treated with antihistamines, not epinephrine, as per the American Academy of Pediatrics guidelines 4, 5

The American College of Allergy, Asthma, and Immunology suggests cetirizine 10 mg once daily as the preferred initial choice for generalized hives due to its rapid relief, although it causes mild sedation in approximately 13.7% of patients 1, 3
Fexofenadine 180 mg once daily is a completely non-sedating alternative, ideal when any sedation is unacceptable, as recommended by the American Academy of Allergy, Asthma, and Immunology 1, 2

The American College of Allergy, Asthma, and Immunology recommends increasing the antihistamine dose up to 4 times the standard dose (e.g., cetirizine 40 mg daily, fexofenadine 720 mg daily) when potential benefits outweigh risks 2, 3

Systemic corticosteroids should never be used as maintenance therapy for chronic urticaria and should only be reserved for short-term control during severe acute flares, as per the American College of Allergy, Asthma, and Immunology guidelines 2

The American Academy of Dermatology recommends identifying and minimizing aggravating factors, including overheating, stress, alcohol, NSAIDs, aspirin, and codeine, while initiating antihistamine therapy 2, 3
Applying emollients regularly for any associated dry skin is suggested by the American Academy of Dermatology 2, 3

The American Geriatrics Society advises against using first-generation antihistamines (diphenhydramine, hydroxyzine) as first-line daytime therapy due to significant sedation, performance impairment, anticholinergic effects, and increased fall risk, particularly in elderly patients 1, 3

The American College of Allergy, Asthma, and Immunology recommends omalizumab 300 mg subcutaneously every 4 weeks as the next step for chronic urticaria, allowing up to 6 months for response 2, 3

The American Geriatrics Society suggests using fexofenadine, loratadine, or desloratadine in elderly patients and avoiding first-generation antihistamines entirely due to increased fall risk and anticholinergic complications 1
The National Kidney Foundation recommends preferring fexofenadine or loratadine in patients with renal impairment and halving the dose of cetirizine and levocetirizine 1, 3